SEMAGLUTIDE IMPROVES LIVER ENZYMES AND FATTY LIVER INDEX IN PATIENTS WITH OBESITY AND CARDIOVASCULAR DISEASE - RESULTS FROM THE SELECT TRIAL

被引：0

作者：

Meyhoefer, Sebastian ^{[1
]}

Cariou, Bertrand ^{[2
]}

Cercato, Cintia ^{[3
]}

Colhoun, Helen ^{[4
]}

Deanfield, John ^{[5
]}

Kjaer, Mette Skalshoi ^{[6
]}

Jeppesen, Ole ^{[6
]}

Lincoff, A. Michael ^{[7
,8
]}

Lingvay, Ildiko ^{[9
]}

Newsome, Phillip ^{[10
,11
]}

Nicholls, Stephen ^{[12
]}

Pelaez, Maria De Los Angeles Quiroga ^{[6
]}

Santini, Ferruccio ^{[13
]}

Sanyal, Arun ^{[14
]}

Kahn, Steven ^{[15
,16
]}

机构：

[1] Novo Nordisk Pharma GmbH, Clin Med & Regulatory, Mainz, Germany

[2] Nantes Univ, CHU Nantes, CNRS, INSERM,Inst Thorax, Nantes, France

[3] Univ Sao Paulo, Hosp Clin, Dept Endocrinol, Obes Unit, Sao Paulo, Brazil

[4] Univ Edinburgh, Inst Genet & Canc, Edinburgh, Midlothian, Scotland

[5] UCL, Inst Cardiovasc Sci, London, England

[6] Novo Nordisk AS, Soborg, Denmark

[7] Cleveland Clin, Cleveland, OH 44106 USA

[8] Case Western Reserve Univ, Lerner Coll Med, Cleveland, OH 44106 USA

[9] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[10] Kings Coll London, Inst Hepatol, London, England

[11] Kings Coll Hosp London, London, England

[12] Monash Univ, Victorian Heart Inst, Melbourne, Vic, Australia

[13] Univ Hosp Pisa, Obes & Lipodystrophy Ctr, Pisa, Italy

[14] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA

[15] VA Puget Sound Hlth Care Syst, Seattle, WA USA

[16] Univ Washington, Seattle, WA 98195 USA

来源：

HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

623

引用

页码：S457 / S459

页数：3

共 50 条

[31] Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
Shao, Ning
Kuang, Hong Yu
Hao, Ming
Gao, Xin Yuan
Lin, Wen Jian
Zou, Wei
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (06) : 521 - 529
[32] Cardiovascular Outcomes and Mortality After Bariatric Surgery in Patients With Nonalcoholic Fatty Liver Disease and Obesity
Krishnan, Arunkumar
Hadi, Yousaf
Alqahtani, Saleh A.
Woreta, Tinsay A.
Fang, Wei
Abunnaja, Salim
Szoka, Nova
Tabone, Lawrence E.
Thakkar, Shyam
Singh, Shailendra
JAMA NETWORK OPEN, 2023, 6 (04) : E237188
[33] Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial
Mogna-Pelaez, Paola
Riezu-Boj, Jose I.
Milagro, Fermin I.
Herrero, Jose I.
Elorz, Mariana
Benito-Boillos, Alberto
Tobaruela-Resola, Ana Luz
Tur, Josep A.
Martinez, J. Alfredo
Abete, Itziar
Zulet, M. Angeles
CLINICAL NUTRITION, 2024, 43 (07) : 1770 - 1781
[34] THE ALCOHOLIC LIVER DISEASE/ NONALCOHOLIC FATTY LIVER DISEASE INDEX ( ANI) IN CLASSIFICATION OF PATIENTS WITH METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE ( MAFLD)
Roy, Akash
Goenka, Usha
Jajodia, Surabhi
Tewari, Awanish
Verma, Nipun
Goenka, Mahesh
HEPATOLOGY, 2023, 78 : S884 - S885
[35] Semaglutide improves cardiovascular outcomes in patients with high risk of metabolic dysfunction-associated steatohepatitis - a subgroup analysis from the SELECT trial
George, Jacob
Meyhofer, Sebastian
Cariou, Bertrand
Cercato, Cintia
Colhoun, Helen
Duun-Henriksen, Anne Katrine
Kliers, Iris
Lincoff, A. Michael
Lingvay, Ildiko
Long, Michelle
Newsome, Philip N.
Nicholls, Stephen
Pelaez, Maria De Los Angeles Quiroga
Santini, Ferruccio
Sanyal, Arun J.
Kahn, Steven
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 68 - 69
[36] Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Incident Cardiovascular Disease: A Narrative Review and Clinical Perspective of Prospective Data
Ghouri, Nazim
Preiss, David
Sattar, Naveed
HEPATOLOGY, 2010, 52 (03) : 1156 - 1161
[37] Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity
Townsend, S. A.
Newsome, P. N.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (04) : 459 - 460
[38] Effect of Beta vulgaris Extract on Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
Afzali, Nikta
Ebadi, Seyed Shayan
Afzali, Hasan
Sharif, Mohammad Reza
Vazirian, Mahdi
Ebadi, Seyed Alireza
Shahkarami, Vahid
Rahimi, Habibollah
HEPATITIS MONTHLY, 2020, 20 (07) : 1 - 8
[39] Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial
Gad, Ahmed I.
Ibrahim, Nevin F.
Almadani, Noura
Mahfouz, Rasha
Nofal, Hanaa A.
El-Rafey, Dina S.
Ali, Hossam Tharwat
EL-Hawary, Amr T.
Sadek, Ayman M. E. M.
DISEASES, 2024, 12 (08)
[40] The Association of Obesity, Metabolic Syndrome, Diabetes, and Cardiovascular Disease with Nonalcoholic Fatty Liver Disease
Bell, David S. H.
SOUTHERN MEDICAL JOURNAL, 2009, 102 (10) : 991 - 992

← 1 2 3 4 5 →